These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 2127299)

  • 1. New ddI information.
    Randall PS
    Minn Med; 1990 Dec; 73(12):12. PubMed ID: 2127299
    [No Abstract]   [Full Text] [Related]  

  • 2. ddI--a good start, but still phase I.
    Fauci AS
    N Engl J Med; 1990 May; 322(19):1386-8. PubMed ID: 2109198
    [No Abstract]   [Full Text] [Related]  

  • 3. New drug therapy for patients with HIV. Nursing implications in the administration of 2',3'-dideoxyinosine (ddI).
    Shay LE; Thomas RV; Wyvill KM; Adamo DO; Jenkins JF
    Cancer Nurs; 1990 Oct; 13(5):269-77. PubMed ID: 2123127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group.
    Jablonowski H; Arasteh K; Staszewski S; Ruf B; Stellbrink HJ; Schrappe M; Stoehr A; Haase W; Schomaker U; von Eisenhart Rothe B
    AIDS; 1995 May; 9(5):463-9. PubMed ID: 7639971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex.
    Yarchoan R; Pluda JM; Thomas RV; Mitsuya H; Brouwers P; Wyvill KM; Hartman N; Johns DG; Broder S
    Lancet; 1990 Sep; 336(8714):526-9. PubMed ID: 1975038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-HIV therapy (1987-1994): from nothing to confusion].
    Lissen E
    Med Clin (Barc); 1995 Apr; 104(12):463-7. PubMed ID: 7739285
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.
    Connolly KJ; Allan JD; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE
    Am J Med; 1991 Nov; 91(5):471-8. PubMed ID: 1659189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promising results for new AIDS/ARC drug.
    Nurs Stand; 1990 Jun 13-19; 4(38):16. PubMed ID: 2116821
    [No Abstract]   [Full Text] [Related]  

  • 9. New treatment being tested against AIDS and ARC.
    Oncology (Williston Park); 1987 Sep; 1(7):11. PubMed ID: 2856351
    [No Abstract]   [Full Text] [Related]  

  • 10. Will new treatment cause remission in AIDS patients?
    Moran EJ
    Hospitals; 1990 Feb; 64(3):72. PubMed ID: 2298431
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase I study of 2',3'-dideoxyinosine: experience with 19 patients at New York University Medical Center.
    Valentine FT; Seidlin M; Hochster H; Laverty M
    Rev Infect Dis; 1990; 12 Suppl 5():S534-9. PubMed ID: 1974725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily.
    Cooley TP; Kunches LM; Saunders CA; Perkins CJ; Kelley SL; McLaren C; McCaffrey RP; Liebman HA
    Rev Infect Dis; 1990; 12 Suppl 5():S552-60. PubMed ID: 1974727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine.
    Kieburtz KD; Seidlin M; Lambert JS; Dolin R; Reichman R; Valentine F
    J Acquir Immune Defic Syndr (1988); 1992; 5(1):60-4. PubMed ID: 1346633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles.
    Yarchoan R; Mitsuya H; Pluda JM; Marczyk KS; Thomas RV; Hartman NR; Brouwers P; Perno CF; Allain JP; Johns DG
    Rev Infect Dis; 1990; 12 Suppl 5():S522-33. PubMed ID: 1974724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AIDS treatment: 'parallel trick' for ddI.
    McGourty C
    Nature; 1989 Oct; 341(6242):474. PubMed ID: 2507927
    [No Abstract]   [Full Text] [Related]  

  • 16. Overview of phase I trials of 2',3'-dideoxyinosine (ddI) conducted on adult patients.
    Rozencweig M; McLaren C; Beltangady M; Ritter J; Canetta R; Schacter L; Kelley S; Nicaise C; Smaldone L; Dunkle L
    Rev Infect Dis; 1990; 12 Suppl 5():S570-5. PubMed ID: 2166965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy.
    Whitfield RM; Bechtel LM; Starich GH
    Alcohol Clin Exp Res; 1997 Feb; 21(1):122-7. PubMed ID: 9046384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From the Food and Drug Administration.
    Nightingale SL
    JAMA; 1989 Nov; 262(18):2503. PubMed ID: 2509741
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trial.
    Chaisson RE; Leuther MD; Allain JP; Nusinoff-Lehrman S; Boone GS; Feigal D; Volberding P
    Arch Intern Med; 1988 Oct; 148(10):2151-3. PubMed ID: 3263098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Didanosine in the treatment of AIDS and AIDS-related complex: a critical appraisal of the dose and frequency of administration.
    Liebman HA; Cooley TP
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S52-8. PubMed ID: 8093847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.